Persistent disparities in diabetes medication receipt by socio-economic disadvantage in Australia.

ABSTRACT:

Background

It is unknown how use of newer glucose-lowering drugs (GLDs) has changed in Australia following the publication of clinical trials demonstrating definitive clinical advantages for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter 2 inhibitors (SGLT2is), and whether this varies by socio-economic disadvantage.

Methods

We included 1,064,645 people with type 2 diabetes registered on the National Diabetes Services Scheme. This cohort was linked to the Pharmaceutical Benefits Scheme database to evaluate trends in diabetes medication receipt and variation by socio-economic disadvantage between 2013 and 2019.

Results

The proportion of people with type 2 diabetes receiving ≥3 GLDs concurrently increased from 12% in 2013 to 25% i

SUBMITTER: Morton JI 

PROVIDER: S-EPMC9545050 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature